Aqua

Specialisation

Retina and Vitreous.

Full title

Open-label phase IV trial to examine the change of vision-related quality of life in subjects with diabetic macular oedema (DMO) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment.

Promoter

Bayer.

Start date

December 2014.

End date

October 2017.

Researchers

Principal: Dr AnnikenBurés.